Good MorningEquity markets moved higher for the 4th consecutive day despite weak labor data. The ADP data shows job growth cooling more than expected in August, suggesting a weak NFP figure on Friday. The news is taken as good news because it shows slowing in the economy, including slowing wage growth, although wage inflation is still running hot. The risk for traders is that the NFP and ADP do not often track in alignment and may provide a different perspective on Friday.
The S&P confirmed a bottom at 4,350 and is now moving higher. The index could move up to retest the recent highs and may surpass that level if this week's data is sufficiently cool. The PCE price index is the wild card; it is due on Thursday and is expected to show core consumer inflation accelerated on a YOY basis compared to last month. If that trend continues, the FOMC should be expected to continue hiking rates regardless of cooling within the labor market. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Technology | |
Ambarella’s (NASDAQ: AMBA) stock shed 20% following the Q2 report and guidance, but don’t read too much bearishness into the news. The company is focused on next-gen computer vision technology with low revenue levels, and it is lightly traded, making it susceptible to bad news.
The ta... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Retail/Wholesale | |
Remember when every car dealer on the street had no inventory and lead times extended up to a year for specific brands? The chip shortage causing supply bottlenecks in motor vehicles is taking a back seat to catch its breath and hopefully never come back into the arena.
What this means for the av... Read the Full Story |
|
Medical | |
Med tech has been on the skids for no fault of its own. It’s not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized. The salient point is that the med tech and med tech stocks market has normalized and pre... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Consumer Discretionary | |
Having at one point last year been down more than 75%, shares of Netflix Inc (NASDAQ: NFLX) have been having what can only be called the mother of all comebacks. They're currently up 160% from the lows twelve months ago, having recently been up as much as 200%, with many of those gains coming this... Read the Full Story |
|
Finance | |
The insurance industry faces many headwinds post-COVID normalization among them. While the headwinds continue to blow, the takeaway for investors is that insurance stocks are lightly valued, they produce cash, they pay solid dividends, margins are improving, and there are speculations of mergers a... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Consumer Discretionary | |
Athletic footwear and apparel maker NIKE Inc. (NYSE: NKE) stock is down 16.7% year-to-date (YTD). The recent earnings warnings from sports retailers DICK’S Sporting Goods Inc. (NYSE: DKS) and Foot Locker Inc. (NYSE: FL) have soured the already weak sentiment in the sector. These warnings imp... Read the Full Story |
|
Technology | |
AI is hot. It is expected to grow at a 50% CAGR or higher for the next several years, which certainly looks true for NVIDIA (NASDAQ: NVDA). While NVIDIA has captured the attention of investors, now there is another opportunity with longer legs than a data-center revolution: embedding AI into the d... Read the Full Story |
|
Technology | | Order has been restored. With the tech-heavy Nasdaq snapping its three-week losing streak, the market’s sector leader is back — at least for now.
By far 2023’s best-performing group, information technology companies are benefiting from job cuts, other cost-saving measures, a semic... Read the Full Story |
|
Retail/Wholesale | |
Organized theft is flipping more than product displays at DICK'S Sporting Goods, Inc. (NYSE: DKS).
The athletic apparel and equipment retailer's shares were turned upside down last week after it announced disappointing second-quarter financials. With Wall Street anticipating a slight year-over-y... Read the Full Story |
|
Retail/Wholesale | |
The dirty laundry keeps piling up for Foot Locker, Inc. (NYSE: FL). Last week, the athletic apparel and sporting goods retailer announced its sixth straight quarter of lower profits and the worst bottom line performance since Covid closures.
Although the result matched Wall Street expectations, a... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. | | View Today's Stock Pick |
|
